Insight Molecular Diagnostics
IMDX
39 hedge funds and large institutions have $18.1M invested in Insight Molecular Diagnostics in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 9 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
0.63% more ownership
Funds ownership: 0.74% → 1.37% (+0.63%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 45 → 39 (-6)
17% less capital invested
Capital invested by funds: $21.7M → $18.1M (-$3.61M)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$13.1M |
| 2 |
Goldman Sachs
New York
|
+$96.5K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$58.7K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$43.1K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$8.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$99.1K |
| 2 |
Bank of New York Mellon
New York
|
-$78K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$34K |
| 5 |
TA
Teachers Advisors
New York
|
-$20K |
IMDX Hedge Fund Activity: Q1 2018 in Review
39 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2018, worth a combined $18.1M — down 17% from $21.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IMDX and 3 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Broadwood Capital, adding an estimated $13.1M. The largest seller was Bridgeway Capital Management, cutting an estimated $99.1K.
- 39 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2018, down from 45 in Q4 2017.
- Funds reported $18.1M of Insight Molecular Diagnostics stock for Q1 2018, down 17% quarter-over-quarter.
- 3 funds opened new Insight Molecular Diagnostics positions in Q1 2018 and 9 closed out, a net change of -6 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2018 was Broadwood Capital, an estimated $13.1M added.
- The largest Insight Molecular Diagnostics seller in Q1 2018 was Bridgeway Capital Management, an estimated $99.1K sold.
Based on aggregated 13F filings for Q1 2018.